Advertisement
Singapore markets close in 3 hours 38 minutes

  • Straits Times Index

    3,281.51
    -11.62 (-0.35%)
     

  • Nikkei

    37,669.40
    -790.68 (-2.06%)
     

  • Hang Seng

    17,261.61
    +60.34 (+0.35%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,140.12
    -2,698.46 (-4.04%)
     

  • CMC Crypto 200

    1,388.73
    -35.37 (-2.48%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,328.80
    -9.60 (-0.41%)
     

  • Crude Oil

    82.94
    +0.13 (+0.16%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.29
    -1.19 (-0.08%)
     

  • Jakarta Composite Index

    7,157.23
    -17.30 (-0.24%)
     

  • PSE Index

    6,580.88
    +8.13 (+0.12%)
     

Analysts Are Bullish on Verastem in September

Daniel Collins
Updated
Analysts Are Bullish on Verastem in September

On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

Continue reading